Volver al Panel








Merck & Company, Inc. (MRK)
Valores intradiarios en tiempo real
Resumen del Mercado
From:
To:
MRK Intraday
No data available
SímboloMRK
Fecha de SalidaJan 2, 1962
CEOMr. Robert M. Davis J.D.
Empleados a Tiempo Completo73k
SectorHealthcare
IndustriaDrug Manufacturers - General
PaísUnited States
BolsaNYSE
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.
Rendimiento
| Período | Rentabilidad % | Cambio de Valor |
|---|---|---|
| 1 Día | +0.67% | +0.89 US$ |
| 5 Días | -9.52% | -14.06 US$ |
| 1 Mes | -10.80% | -16.18 US$ |
| 6 Meses | +9.22% | +11.29 US$ |
Analizando el Mercado con IA
Evaluando los últimos 30 días de historial y métricas fundamentales de MRK...
Estadísticas Clave
Cap. de Mercado
329.65B
Relación P/E
135.07
Rend. de Div.
2.65%
Máx. 52 Semanas
$156.92
Mín. 52 Semanas
$95.36
Consenso de Analistas
CONSENSOCompra
ALCISTA1967.9%
NEUTRAL932.1%
BAJISTA00.0%
Objetivos de Precios de Analistas a 52 Semanas
Objetivo Mín.
$105.00
$105.00
Objetivo Máx.
$186.00
$186.00
Actual$133.70
Objetivo Prom.$161.53
Recomendaciones de Analistas
Precio Objetivo:$161.53($105.00 - $186.00)
¿Buscas más valores? Explóralos en el screener
Pensamientos de la Comunidad
Comparta su análisis y sentimiento sobre MRK
Únase a la comunidad para compartir su análisis
Últimas Noticias para MRK

What A Cancer Vaccine Stumble Means For Moderna Stock
Trefis•20 nov 2026, 18:29

What Does Eli Lilly Offer That Merck Does Not?
Trefis•20 nov 2026, 16:59

MSD and Isomorphic join forces to develop oncology drugs
Pharmaceutical Technology•20 nov 2026, 15:59



Should You Buy Bristol Myers Squibb Stock At Today's Discount?
Trefis•20 nov 2026, 14:51

HALO Faces Legal Setback in Germany Over MRK's Keytruda SC, Stock Down
Zacks•20 nov 2026, 14:10

Which Merck ETF Best Balances Its Drug Upside And Risks?
Simply Wall St.•20 nov 2026, 13:08
Merck Says Sac-TMT Meets Endpoint of Overall Survival in Phase 3 Trial
MT Newswires•20 nov 2026, 12:20
